Intuitive Surgical, Inc. (ISRG) Quick Ratio
- Quick ratio · latest quarter: Value 3.58×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 3.58× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $6.89B ÷ $1.92B ≈ 3.58× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 6.89B USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 1.92B USD | Liabilities, Current |
| Cash and equivalents | 2.76B USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 2.46B USD | Marketable Securities, Current |
| Customer receivables | 1.67B USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 2.03B USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $6.89B | $1.92B | $2.76B | $2.46B | $1.67B | $2.03B | 3.58× |
| 2026-03-31 | $6.11B | $1.91B | $2.01B | $2.51B | $1.60B | $1.95B | 3.20× |
| 2025-12-31 | $7.46B | $2.01B | $3.37B | $2.57B | $1.53B | $1.84B | 3.72× |
| 2025-09-30 | $6.17B | $1.80B | $2.81B | $2.10B | $1.26B | $1.78B | 3.42× |
| 2025-06-30 | $6.60B | $1.69B | $3.40B | $1.92B | $1.27B | $1.67B | 3.90× |
| 2025-03-31 | $5.73B | $1.54B | $2.57B | $1.94B | $1.22B | $1.55B | 3.73× |
| 2024-12-31 | $5.24B | $1.75B | $2.03B | $1.99B | $1.23B | $1.49B | 3.00× |
| 2024-09-30 | $5.38B | $1.68B | $2.41B | $1.82B | $1.15B | $1.48B | 3.21× |
| 2024-06-30 | $5.87B | $1.49B | $3.04B | $1.72B | $1.11B | $1.38B | 3.94× |
| 2024-03-31 | $5.93B | $1.38B | $2.84B | $1.96B | $1.13B | $1.30B | 4.31× |
| 2023-12-31 | $6.35B | $1.66B | $2.75B | $2.47B | $1.13B | $1.22B | 3.83× |
| 2023-09-30 | $7.44B | $1.68B | $3.60B | $2.87B | $962.70M | $1.15B | 4.44× |
| 2023-06-30 | $6.70B | $1.54B | $3.44B | $2.36B | $904.20M | $1.01B | 4.36× |
| 2023-03-31 | $5.62B | $1.31B | $2.14B | $2.55B | $925.30M | $946.60M | 4.30× |
| 2022-12-31 | $5.06B | $1.42B | $1.58B | $2.54B | $942.10M | $893.20M | 3.56× |
| 2022-09-30 | $5.16B | $1.23B | $1.54B | $2.78B | $849.60M | $837.10M | 4.19× |
| 2022-06-30 | $5.28B | $1.18B | $1.54B | $2.90B | $838.50M | $724.00M | 4.49× |
| 2022-03-31 | $4.89B | $1.11B | $1.10B | $2.88B | $906.10M | $653.00M | 4.40× |
| 2021-12-31 | $4.99B | $1.15B | $1.29B | $2.91B | $782.70M | $587.10M | 4.34× |
| 2021-09-30 | $4.78B | $1.03B | $1.35B | $2.74B | $695.00M | $584.90M | 4.66× |
| 2021-06-30 | $5.14B | $1.00B | $1.62B | $2.82B | $699.90M | $569.70M | 5.12× |
| 2021-03-31 | $5.21B | $904.60M | $1.40B | $3.16B | $654.30M | $576.80M | 5.76× |
| 2020-12-31 | $5.76B | $965.20M | $1.62B | $3.49B | $645.50M | $601.50M | 5.96× |
| 2020-09-30 | $5.31B | $894.70M | $1.37B | $3.35B | $588.60M | $662.90M | 5.93× |
| 2020-06-30 | $5.00B | $924.80M | $2.04B | $2.45B | $508.80M | $645.50M | 5.40× |
| 2020-03-31 | $3.78B | $945.90M | $1.22B | $2.03B | $527.60M | $620.30M | 4.00× |
| 2019-12-31 | $3.87B | $1.03B | $1.17B | $2.05B | $645.20M | $595.50M | 3.75× |
| 2019-09-30 | $3.54B | $930.90M | $969.60M | $1.93B | $639.00M | $579.60M | 3.80× |
| 2019-06-30 | $3.35B | $807.50M | $790.30M | $1.93B | $633.40M | $512.80M | 4.15× |
| 2019-03-31 | $3.36B | $740.20M | $875.70M | $1.93B | $547.60M | $468.30M | 4.53× |
| 2018-12-31 | $3.75B | $820.60M | $857.90M | $2.21B | $682.30M | $409.00M | 4.56× |
| 2018-09-30 | $3.72B | $703.30M | $1.01B | $2.13B | $580.40M | $370.10M | 5.28× |
| 2018-06-30 | $3.46B | $666.40M | $1.20B | $1.73B | $532.50M | $331.50M | 5.20× |
| 2018-03-31 | $2.99B | $581.20M | $974.70M | $1.54B | $474.90M | $283.60M | 5.15× |
| 2017-12-31 | $2.47B | $704.10M | $648.20M | $1.31B | $511.90M | $241.20M | 3.51× |
| 2017-09-30 | $2.61B | $615.70M | $875.00M | $1.27B | $468.00M | $225.20M | 4.25× |
| 2017-06-30 | $2.30B | $599.80M | $696.50M | $1.13B | $481.10M | $214.20M | 3.84× |
| 2017-03-31 | $1.88B | $558.20M | $708.60M | $756.20M | $412.90M | $213.50M | 3.36× |
| 2016-12-31 | $2.98B | $596.50M | $1.04B | $1.52B | $430.20M | $182.30M | 5.00× |
| 2016-09-30 | $2.65B | $528.10M | $1.02B | $1.19B | $432.00M | $183.50M | 5.01× |
| 2016-06-30 | $2.59B | $489.50M | $1.19B | $990.30M | $403.80M | $169.20M | 5.29× |
| 2016-03-31 | $2.13B | $452.90M | $980.50M | $827.90M | $325.90M | $163.00M | 4.71× |
| 2015-12-31 | $1.95B | $491.90M | $714.60M | $845.20M | $394.30M | $167.90M | 3.97× |
| 2015-09-30 | $2.07B | $478.60M | $868.20M | $871.50M | $334.70M | $194.00M | 4.33× |
| 2015-06-30 | $1.88B | $474.40M | $915.40M | $646.10M | $321.50M | $201.30M | 3.97× |
| 2015-03-31 | $1.65B | $456.90M | $701.10M | $661.10M | $292.40M | $202.40M | 3.62× |
| 2014-12-31 | $1.55B | $501.20M | $600.30M | $632.20M | $315.10M | $181.70M | 3.09× |
| 2014-09-30 | $1.27B | $480.50M | $493.00M | $521.30M | $259.10M | $198.90M | 2.65× |
| 2014-06-30 | $1.25B | $495.90M | $507.60M | $471.00M | $271.10M | $202.40M | 2.52× |
| 2014-03-31 | $1.80B | $459.50M | $814.00M | $745.30M | $239.10M | $185.50M | 3.91× |
| 2013-12-31 | $1.70B | $380.90M | $782.10M | $621.40M | $301.40M | $179.60M | 4.48× |
| 2013-09-30 | $1.49B | $367.30M | $586.80M | $626.10M | $280.60M | $200.10M | 4.07× |
| 2013-06-30 | $1.65B | $390.90M | $432.70M | $857.50M | $358.60M | $169.30M | 4.22× |
| 2013-03-31 | $1.70B | $377.60M | $427.50M | $930.70M | $345.10M | $135.50M | 4.51× |
| 2012-12-31 | $1.69B | $401.60M | $553.70M | $770.70M | $370.30M | $121.50M | 4.22× |
| 2012-09-30 | $1.48B | $364.90M | $396.20M | $745.20M | $336.20M | $125.80M | 4.05× |
| 2012-06-30 | $1.54B | $346.80M | $484.40M | $728.10M | $323.20M | $119.40M | 4.43× |
| 2012-03-31 | $1.27B | $313.60M | $325.90M | $645.40M | $299.70M | $118.80M | 4.05× |
| 2011-12-31 | $1.33B | $320.60M | $465.80M | $563.40M | $297.90M | $112.10M | 4.14× |
| 2011-09-30 | $1.18B | $284.10M | $298.20M | $612.40M | $265.10M | $108.60M | 4.14× |
| 2011-06-30 | $1.24B | $274.00M | $382.00M | $611.90M | $250.30M | $100.10M | 4.54× |
| 2011-03-31 | $1.35B | $252.30M | $449.80M | $640.00M | $259.90M | $93.30M | 5.35× |
| 2010-12-31 | $1.16B | $273.80M | $279.80M | $630.60M | $246.80M | $86.80M | 4.23× |
| 2010-09-30 | $1.19B | $267.30M | $382.00M | $598.90M | $207.90M | $85.00M | 4.45× |
| 2010-06-30 | $1.16B | $243.30M | $420.00M | $547.90M | $194.70M | $74.00M | 4.78× |
| 2010-03-31 | $923.60M | $173.80M | $313.60M | $429.80M | $180.20M | $68.50M | 5.31× |
| 2009-12-31 | $760.82M | $202.77M | $221.44M | $334.00M | $205.38M | $57.60M | 3.75× |
| 2009-09-30 | $699.33M | $185.60M | $206.09M | $306.70M | $186.53M | $56.65M | 3.77× |
| 2009-06-30 | (m) | $179.00M | $173.42M | (m) | $175.22M | $59.25M | (m) |
| 2009-03-31 | (m) | (m) | $96.60M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $164.52M | $194.62M | (m) | $170.11M | $63.46M | (m) |
| 2008-09-30 | (m) | (m) | $227.61M | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | $223.02M | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | (m) | $122.83M | (m) | (m) | (m) | (m) |
| 2006-12-31 | (m) | (m) | $34.39M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Edwards Lifesciences Corp (EW) | United States | $49.409B | 51.96 |
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |